Forecast Of The Day: Boston Scientific
What?
Boston Scientific’s (NYSE:BSX) Revenue from Endoscopy declined from around $1.9 billion in 2019 to about $1.8 billion in 2020. However, Trefis expects the number to rise to about $2.2 billion in 2021 and $2.4 billion in 2022. Endoscopy devices are used to diagnose and treat gastrointestinal (GI) and pulmonary conditions, and use less invasive technologies.
Why?
- Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
- What’s Next For Boston Scientific Stock After 5% Gains In A Week?
- Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
- Which Is A Better Buy – Boston Scientific Stock Or Abbott?
- What’s Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
- New Product Launches To Aid Boston Scientific’s Q1
While revenues saw a dip in 2020 due to the Covid-19 pandemic, which resulted in a decline in elective surgeries, we expect sales to pick up from 2021 driven by the introduction of new products and international expansion.
So What?
We think the projected post-Covid growth isn’t fully priced into Boston Scientific’s stock yet. We value the stock at about $50 per share, a premium of about 10% versus the current market price.
See Our Complete Analysis For Boston Scientific
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams